WARN : Please note that some of the values may not be in base currency

Fundamental Analysis of Spero Therapeutics Inc - Growth / Value Index


SPRO - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Poor Score of 26.56
   Price to Book Ratio of 590.78 suggesting that it is very expensive
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 895.60 -52.20 -3954.39 %
Price to Book 278.38 0.788 0.151 % 0.884
Price to Sales 191.80 1.11 -0.991 %
Enterprise Value to EBITDA Multiple 0.552 -8.34 -822.99 %


SPRO - Profitability Highlights

Profitability Analysis

   Tsr Profitability Index - Good Score of 77.50
   During the past twelve months, the company has given a strong Return On Equity of 33.37%
   All key Trailing Twelve Months Margin growing by 15 %
   Piotroski F Score - Stable Value of 5.0
   Annual Net Profit in last 3 years is trending up
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   EBITDA is continuously increasing for last 3 Years
   Steady Growth in EPS for last four quarters
   Good Net Margin of 23.28% is achieved by the company
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 31.08 -1.51 97.53 % -13.16
Return On Asset 17.50 -0.885 97.62 % -7.55
Net Profit Margin 21.42 -2.12 97.56 % -136.71
Operating Profit Margin 18.33 2.77 103.51 % -150.88
EBITDA Margin 18.36 -1.52 98.04 % -150.88


Highlights
Market Cap85689.71 K
Enterprise Value11074.71 K
Price/Book TTM278.38
Outstanding Share53892.90 K
Float/ Outstanding Share73.85%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No5.60
Peter Lynch Ratio0
Piotroski F Score5.00
Altman Z Score-1.31
Sloan Ratio-0.168
Peter Lynch Fair Value0.0444


SPRO - Growth Highlights

Growth Analysis

   Short term positive trend in total sale and net profit
   STRONG JUMP IN NET SALE : YoY growth
   Tremendous increasing trend in total sale last 3 year
   Quarterly sales in last 5 years is trending up
   Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 109283 K 42.39 % 87.10 %
Gross Profit 109245 K 80.10 % 87.09 %
EBITDA 20068.00 K 97.20 % 128.61 %
Net Profit 23404.00 K 96.52 % 124.75 %
EPS 0.0018 97.53 % NA


SPRO - Stability Highlights

Stability Analysis

   Tsr Stability Index - Good Score of 66.07
   Altman Z Score of -1.31 suggest high risk
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0161 -27.79 % 0.0179
Cash Ratio 2.05 -59.23 %
Quick Ratio 3.53 -35.23 % 3.35
Shareholders Equity 58.61 -3.68 %
Debt to EBITDA -1.49 -3534.32 %


Historical Valuation Ratios of Spero Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Spero Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Spero Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Spero Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)